Influenza virus vaccine - Denka Seiken

Drug Profile

Influenza virus vaccine - Denka Seiken

Alternative Names: DNK FLU; DNK-651

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Denka Seiken
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Influenza virus infections

Most Recent Events

  • 01 Oct 2017 Phase-II clinical trials in Influenza virus infections (In adults, In adolescents, In children, In volunteers, Prevention) in Japan (SC) (JapicCTI-173720)
  • 29 Sep 2017 Denka Seiken completes the phase I DNK-651-1 trial in Influenza virus infections (In adults, In the elderly, In volunteers, Prevention) in Japan (Intradermal) (JapicCTI-163226)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top